Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Appointed COO
|
|
Pharma-Bio Serv, Inc. (PBSV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/31/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2023 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2023 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2023 were approximately $4.2 million, a net decrease of approximately $0.8 million when compared to the same period last year. Net income for the quarter ended January 31, 2023 was approximately $0.4 million, an increase of approximately $0.1 million when compared to the same period last year. "This quarter we were able to successfully maximize our resources in more profitable markets. This strategy yielded a positive effect on our overall g..." |
|
| 03/17/2023 |
10-Q
| Quarterly Report for the period ended January 31, 2023 |
| 03/08/2023 |
4
| Sanchez Altura Victor (President and CEO) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Paid exercise price by delivering 7,167 shares
@ $1.15, valued at
$8.2k
Exercised 8,325 options
@ $0.99, valued at
$8.2k
|
|
| 03/08/2023 |
4
| LASANTA PEDRO J (CFO) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Paid exercise price by delivering 76,522 shares
@ $1.15, valued at
$88k
Paid exercise price by delivering 7,167 shares
@ $1.15, valued at
$8.2k
Exercised 100,000 options
@ $0.88, valued at
$88k
Exercised 8,325 options
@ $0.99, valued at
$8.2k
|
|
| 03/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / March 1, 2023 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of $0.075 per share for shareholders. The Special Dividend will be payable on or about April 14, 2023 to shareholders of record at the close of business on March 29, 2023. Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life scie..." |
|
| 02/09/2023 |
8-K
| Quarterly results |
| 02/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Pharma-Bio Serv Retains Investment Banking Firm ACP Capital to Provide Investment Banking and M&A Advisory Services DORADO, PUERTO RICO / ACCESSWIRE / February 7, 2023 / Pharma-Bio Serv, Inc. , a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, announced today that it has retained ACP Capital Markets LLC for investment banking and M&A advisory services. ACP Capital Markets is a specialized investment bank focused on capital markets and advisory assignments. ACP’s capital markets unit specializes in private equity and debt placements while its M&A and Advisory practice is globally focused, covering both public and private marke..." |
|
| 01/30/2023 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / January 30, 2023 / Pharma-Bio Serv, Inc. , is a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries. Today, Pharma-Bio Serv announced that revenues for the year ended October 31, 2022 were approximately $19.4 million, a decrease of approximately $0.7 million when compared to last year. Additionally, net income for the year ended October 31, 2022 was approximately $1.0 million, an improvement of approximately $3.0 million when compared to last year. The net income variance is mostly due to the recording of an account receivable provision of approximately $5.2 million in 2021 which was partially of..." |
|
| 01/30/2023 |
10-K
| Annual Report for the period ended October 31, 2022 |
| 01/11/2023 |
4
| WIESEN IRVING L (Director) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Granted 20,000 options
@ $0.79, valued at
$15.8k
|
|
| 01/11/2023 |
4
| SPINDEL HOWARD (Director) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Paid exercise price by delivering 13,165 shares
@ $0.79, valued at
$10.4k
Gifted 6,835 shares
@ $0
Gifted 6,835 shares
@ $0
Exercised 20,000 options
@ $0.52, valued at
$10.4k
Granted 20,000 options
@ $0.79, valued at
$15.8k
|
|
| 01/11/2023 |
4
| MICHEL KIRK WHEELER (Chairman) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Granted 20,000 options
@ $0.79, valued at
$15.8k
|
|
| 01/11/2023 |
4
| Perlysky Dov (Director) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Granted 20,000 options
@ $0.79, valued at
$15.8k
|
|
| 09/14/2022 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2022 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm providing services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2022 were approximately $4.8 and $14.8 million, respectively. This represents a decrease of approximately $0.2 million and an increase of $0.2 million, for three and nine months respectively, when compared to the same periods last year. Net income for the three and nine months ended July 31, 2022 was approximately $0.3 and $0.8 million, respectively, a decrease for both periods of approximately $2.0 million when compared to the sa..." |
|
| 09/14/2022 |
10-Q
| Quarterly Report for the period ended July 31, 2022 |
| 06/24/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
10-Q
| Quarterly Report for the period ended April 30, 2022 |
| 05/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/17/2022 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2022 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2022 were approximately $5.0 million, an increase of approximately $0.5 million when compared to the same period last year. Net income for the quarter ended January 31, 2022 was approximately $0.3 million, reflecting no significant change when compared to the same period last year. “Our efforts to diversify and expand our geographical revenue should be noted in this quarter’s results. The continental US and Europe consulting markets represen..." |
|
| 03/17/2022 |
10-Q
| Quarterly Report for the period ended January 31, 2022 |
| 02/28/2022 |
10-K/A
| Annual Report for the period ended October 31, 2021 [amend] |
| 02/14/2022 |
8-K
| Quarterly results |
| 02/11/2022 |
10-K
| Annual Report for the period ended October 31, 2021 |
| 02/01/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 01/12/2022 |
4
| MICHEL KIRK WHEELER (Chairman) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Granted 20,000 options
@ $0.97, valued at
$19.4k
|
|
| 01/12/2022 |
4
| WIESEN IRVING L (Director) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Granted 20,000 options
@ $0.97, valued at
$19.4k
|
|
| 01/12/2022 |
4
| SPINDEL HOWARD (Director) has filed a Form 4 on Pharma-Bio Serv, Inc.|
Txns:
| Granted 20,000 options
@ $0.97, valued at
$19.4k
|
|
|
|
|